[Anesthesia in malignant hyperthermia].
Malignant hyperthermia is a condition for which the anesthesiologist must be prepared to take specific measures. Associated mortality is high despite correct diagnosis and, occasionally, the right treatment. Malignant hyperthermia is rare in Spain, however, and perhaps for this reason the Spanish public health authorities have not made an effort to respond to persistent calls for a national reference center for study and diagnosis, such as can be found in other European countries. The problem of malignant hyperthermia may become worse in the near future due to changes in the population brought about by immigration. It is therefore necessary to establish appropriately revised protocols and action plans to cope with this possibility. A reference center cannot be created by individuals, but we can become more aware of the need to establish up-to-date protocols in our departments in order to be prepared for this situation.
Ortiz Gómez
J R
JR
Servicio de Anestesiología y Reanimación, Hospital García Orcoyen, Estella, Navarra. jortizgo@cfnavarra.es
D000293:Adolescent; D000328:Adult; D000368:Aged; D018685:Anesthetics, Inhalation / Q000009:adverse effects* / Q000494:pharmacology; D002110:Caffeine / Q000009:adverse effects / Q000494:pharmacology; D020013:Calcium Signaling / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D003937:Diagnosis, Differential; D018740:Genetic Heterogeneity; D020022:Genetic Predisposition to Disease; D006221:Halothane / Q000009:adverse effects / Q000494:pharmacology; D006801:Humans; D015994:Incidence; D007223:Infant; D007253:Information Centers; D008305:Malignant Hyperthermia / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000235:genetics / Q000517:prevention & control*; D008875:Middle Aged; D016343:Monitoring, Intraoperative; D009119:Muscle Contraction / Q000187:drug effects; D009467:Neuromuscular Depolarizing Agents / Q000009:adverse effects* / Q000494:pharmacology; D011300:Preoperative Care; D019837:Ryanodine Receptor Calcium Release Channel / Q000187:drug effects / Q000235:genetics / Q000502:physiology; D013030:Spain / Q000453:epidemiology
D018685:Anesthetics, Inhalation; D009467:Neuromuscular Depolarizing Agents; D019837:Ryanodine Receptor Calcium Release Channel; D002110:Caffeine; D006221:Halothane